Abstract
Hypertension and cardiac arrhythmias commonly coexist in many patients. In this review, we will initially discuss arrhythmogenesis in hypertension, with particular emphasis on atrial and ventricular tachyarrhythmias and sudden cardiac death, whilst in the final part, we will focus our attention on the effects of anti-hypertensive therapies on supra-ventricular and ventricular arrhythmias and on sudden cardiac death prevention. Many patients with atrial fibrillation or frequent premature ventricular contractions have hypertension, and both need to be managed appropriately. Furthermore, hypertensive left ventricular hypertrophy could cause a wide variety of ventricular arrhythmias, which could end in sudden cardiac arrest. Most anti-hypertensive therapies, such as the β-blockers or ACE inhibitors, by slowing or interrupting the progression towards atrial and ventricular remodelling might exert some anti-arrhythmic effect, thus reducing the risk of sudden cardiac death in these patients.
Keywords: arrhythmias, Hypertension
Current Pharmaceutical Design
Title: Hypertension and Concurrent Arrhythmias
Volume: 9 Issue: 21
Author(s): Federico Lombardi and Paolo Terranova
Affiliation:
Keywords: arrhythmias, Hypertension
Abstract: Hypertension and cardiac arrhythmias commonly coexist in many patients. In this review, we will initially discuss arrhythmogenesis in hypertension, with particular emphasis on atrial and ventricular tachyarrhythmias and sudden cardiac death, whilst in the final part, we will focus our attention on the effects of anti-hypertensive therapies on supra-ventricular and ventricular arrhythmias and on sudden cardiac death prevention. Many patients with atrial fibrillation or frequent premature ventricular contractions have hypertension, and both need to be managed appropriately. Furthermore, hypertensive left ventricular hypertrophy could cause a wide variety of ventricular arrhythmias, which could end in sudden cardiac arrest. Most anti-hypertensive therapies, such as the β-blockers or ACE inhibitors, by slowing or interrupting the progression towards atrial and ventricular remodelling might exert some anti-arrhythmic effect, thus reducing the risk of sudden cardiac death in these patients.
Export Options
About this article
Cite this article as:
Lombardi Federico and Terranova Paolo, Hypertension and Concurrent Arrhythmias, Current Pharmaceutical Design 2003; 9 (21) . https://dx.doi.org/10.2174/1381612033454496
DOI https://dx.doi.org/10.2174/1381612033454496 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Macrophage Infiltration, Lectin-Like Oxidized-LDL Receptor-1, and Monocyte Chemoattractant Protein-1 are reduced by Chronic HMG-CoA Reductase Inhibition
Current Neurovascular Research Modeling the Interactions Between α1-Adrenergic Receptors and Their Antagonists
Current Computer-Aided Drug Design Perspectives on the Tertiary Prevention Strategy for Alzheimer’s Disease
Current Alzheimer Research The Etiology of Hypertension in the Metabolic Syndrome Part Three: The Regulation and Dysregulation of Blood Pressure
Current Vascular Pharmacology Organotypic Brain Slices of ADULT Transgenic Mice: A Tool to Study Alzheimer’s Disease
Current Alzheimer Research Antioxidants in the Treatment of Diabetes
Current Diabetes Reviews Tako-tsubo Cardiomyopathy: A Review of the Literature
Current Cardiology Reviews Correlation between Decreased Parasympathetic Activity and Reduced Cerebrovascular Reactivity in Patients with Lacunar Infarct
Current Neurovascular Research Gastrointestinal Hemorrhage is Associated with Mortality after Acute Ischemic Stroke
Current Neurovascular Research Superoxide Dismutases: Anti- Versus Pro- Oxidants?
Anti-Cancer Agents in Medicinal Chemistry Cardiovascular Concern of 5-HT2B Receptor and Recent Vistas in the Development of Its Antagonists
Cardiovascular & Hematological Disorders-Drug Targets Medication Non-adherence in Patients with Osteoporosis: Implications for Clinical Pharmacists and Osteoporosis Care Providers
Current Clinical Pharmacology Lead (Pb) in Alzheimer’s Dementia: A Systematic Review of Human Case- Control Studies
Current Alzheimer Research Efficacy of Zofenopril Alone or in Combination with Hydrochlorothiazide in Patients with Kidney Dysfunction
Current Clinical Pharmacology Adverse Drug Reactions and Safety Considerations of NSAIDs: Clinical Analysis
Current Drug Safety Recent Progress in Molecular Mechanisms of Angiotensin II Type 1 and 2 Receptors
Current Pharmaceutical Design Racing of the Biological Pacemaker
Recent Patents on DNA & Gene Sequences Gene Therapy for Cardiovascular Diseases
Current Pharmaceutical Design The Effects of Interleukin-10 on the Expression of Fas and FasL in Rat Hepatic Stellate Cells
Medicinal Chemistry The Role of the Osteoprotegerin/RANKL/RANK System in Diabetic Vascular Disease
Current Medicinal Chemistry